INARI MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.75 USD | -1.19% |
|
+4.57% | -29.53% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 599M | Sales 2025 * | 705M | Capitalization | 2.66B |
|---|---|---|---|---|---|
| Net income 2024 * | -49M | Net income 2025 * | 8M | EV / Sales 2024 * | 4.31 x |
| Net cash position 2024 * | 80.82M | Net cash position 2025 * | 115M | EV / Sales 2025 * | 3.61 x |
| P/E ratio 2024 * |
-50
x | P/E ratio 2025 * |
323
x | Employees | 1,300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.43% |
More Fundamentals
* Assessed data
More news
Latest transcript on Inari Medical, Inc.
More recommendations
More press releases
| 1 day | -1.19% | ||
| 1 week | +4.57% | ||
| Current month | +22.52% | ||
| 1 month | +18.22% | ||
| 3 months | -21.71% | ||
| 6 months | -21.09% | ||
| Current year | -29.53% |
1 week
43.61
47.31
1 month
36.7347.31
Current year
36.7366.35
1 year
36.7371.85
3 years
36.73100.00
5 years
36.73127.42
10 years
36.73127.42
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Hykes
CEO | Chief Executive Officer | 51 | 17-08-31 |
Mitchell Hill
DFI | Director of Finance/CFO | 65 | 19-02-28 |
Norman Nie
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jon Root
BRD | Director/Board Member | 64 | 11-08-31 |
Don Milder
CHM | Chairman | 70 | 11-08-31 |
Catherine Szyman
BRD | Director/Board Member | 57 | 19-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.94% | 14 M€ | -3.66% | ||
| 0.15% | 1,085 M€ | +8.83% | - | |
| 0.08% | 430 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 45.75 | -1.19% | 887,809 |
| 24-05-16 | 46.3 | -1.47% | 1,113,351 |
| 24-05-15 | 46.99 | +3.27% | 815,560 |
| 24-05-14 | 45.5 | -0.18% | 885,041 |
| 24-05-13 | 45.58 | +4.18% | 1,312,145 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Inari Medical, Inc. is a medical device company. The Companyâs products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
45.75
USD
Average target price
64.4
USD
Spread / Average Target
+40.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.53% | 2.66B | |
| +73.24% | 12.39B | |
| -19.09% | 7.89B | |
| +5.88% | 6.59B | |
| +13.24% | 5.43B | |
| +38.48% | 4.96B | |
| -17.30% | 4.72B | |
| -19.78% | 4.02B | |
| +47.29% | 2.37B | |
| -2.10% | 1.96B |
- Stock Market
- Equities
- NARI Stock
